Navigation Links
Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program
Date:2/4/2009

SWARTZ CREEK, Mich., Feb. 4 /PRNewswire/ -- Diplomat Specialty Pharmacy is pleased to announce two new "Navigator" initiatives (disease management programs). As of January 2009, DSP launched both a Hemophilia and IVIG Navigator Program. In addition, Scott Reed has joined Diplomat as National Sales Manager for both programs. Reed is a graduate of Indiana University and has over 18 years of pharmaceutical sales experience. Most recently Reed was a Hematology Account Executive with Bayer HealthCare, prior to that he was a Sales Manager with ZLB (CSL Behring). Reed will report directly to Mark Neville, Vice President of Sales and Marketing.

Reed will team with Diplomat's Director of Pharmacy Development and Operations, Rinku A. Patel, RPh, PharmD. Patel will lead the development of program infrastructure to support Diplomat's Hemophilia and IVIG Navigator programs.

"Hemophilia patients require a very high touch patient care model and Diplomat's services are a perfect fit for these patients," stated Patel. "Diplomat's Navigator Programs, through direct patient care and coordination with providers, improve access, tolerance, and compliance resulting in enhanced clinical and economic outcomes for patients with bleeding disorders."

"Diplomat Specialty Pharmacy is very excited to welcome Scott to our team," said Neville. "Under Dr. Patel's clinical expertise, Scott will lead our efforts in launching Diplomat's national program that will provide the highest level of clinical care to patients with bleeding disorders and IVIG needs."

"After spending many years in the hemophilia marketplace, I am happy to join the team at Diplomat Specialty Pharmacy," said Reed. "A hemophilia and IVIG program can improve medication adherence, control costs and improve quality of life. Diplomat's Disease Management programs are the most comprehensive and innovative programs available. I look forward to being a part of the great things that are happening at Diplomat Specialty Pharmacy."

About Diplomat Specialty Pharmacy

Diplomat Specialty Pharmacy is the nation's largest independently held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Crohn's and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio-Identical Hormone Replacement Therapy and Specialty Compounding. The company also specializes in Disease Management programs for Chronic Kidney Disease patients, as well as Home and Out-Patient Infusion. With locations in Flint, Swartz Creek and Grand Rapids, MI; Cleveland, OH; Chicago, IL; and Ft. Lauderdale, Florida; Diplomat services the specialty pharmacy needs of patients and physicians nationwide.

    For more information contact:
    Kathy Karns
    kkarns@diplomatpharmacy.com
    810-720-4452

'/>"/>
SOURCE Diplomat Specialty Pharmacy
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
2. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
3. Diplomat Specialty Pharmacy Hires National Accounts Manager to Expand Multiple Sclerosis Program
4. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
5. Diplomats 2008 Patient Satisfaction Survey Sets the Bar for Specialty Pharmacy Industry
6. Diplomat Specialty Pharmacy Hires Rinku A. Patel, PharmD as Director of Pharmacy Development and Operations
7. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
8. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
9. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
10. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
11. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... Switzerland (PRWEB) , ... January ... ... provider of advanced software solutions for pharmaceutical research and development (R&D), today ... expertise in omic data analysis and interpretation for the rapidly evolving field ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
Breaking Biology Technology:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied ... that the global biometric technology market is expected to generate revenue of $10.72 billion ... Continue Reading ... Allied Market Research ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):